NCT06372574View on ClinicalTrials.gov

A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2024

Primary Completion Date

February 1, 2028

Study Completion Date

February 1, 2028

Conditions
Refractory CancerRecurrent CancerSolid Tumor, Adult
Interventions
DRUG

RO7617991

RO7617991 will be administered by intravenous (IV) infusion. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

DRUG

Tocilizumab

Tocilizumab 8 mg/kg IV will be administered to patients when necessary to treat potential cytokine release syndrome (CRS), as described in the protocol.

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY